Effects of Bezafibrate Treatment in a Patient and a Carrier With Mutations in the PNPLA2 Gene, Causing Neutral Lipid Storage Disease With Myopathy
Year: 2013
Type: article
Abstract: Neutral lipid storage disease with myopathy (NLSDM) is a rare but severe genetic disorder characterized by excessive lipid accumulation in tissues including skin, bone marrow, heart, liver, and muscles. Clinically, NLSDM patients present with severe dilated cardiomyopathy, skeletal muscle myopathy, and insulin resistance.1 NLSDM is caused by a defect in the PNPLA2 gene encoding the enzyme adipose triglyceride lipase (ATGL),2 which catalyzes the breakdown of triglycerides in multiple tissues and is the rate-limiting step of lipolysis. Although heterozygous carriers and homozygous patients both present with similar clinical symp-toms, the severity of these symptoms in homozygous patients is more dramatic, leading to premature death attributed to dilated cardiomyopathy in some patients.1,2 To date, the only available treatment is strict dietary guidelines and is focused on treating the comorbidities rather than targeting the primary defect.
Source: Circulation Research
Authors: Tineke van de Weijer, Bas Havekes, Lena Bilet, Joris Hoeks, Lauren Sparks, Madeleen Bosma, Sabina Paglialunga, Johanna Jorgensen, Mirian C.H. Janssen, Gert Schaart, Hans Sauerwein, Joep L. Smeets, Joachim Wildberger, Rudolf Zechner, Vera B. Schrauwen-Hinderling, Matthijs K.C. Hesselink, Patrick Schrauwen
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2010426240
